Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Mersana Therapeutics, Inc. | mrsn-20191231ex321b1e22e.htm |
| EX-31.2 - EX-31.2 - Mersana Therapeutics, Inc. | mrsn-20191231ex312f3da01.htm |
| EX-31.1 - EX-31.1 - Mersana Therapeutics, Inc. | mrsn-20191231ex3118a639a.htm |
| EX-21.1 - EX-21.1 - Mersana Therapeutics, Inc. | mrsn-20191231ex211c1cc4c.htm |
| EX-4.4 - EX-4.4 - Mersana Therapeutics, Inc. | mrsn-20191231ex44aee8769.htm |
| 10-K - 10-K - Mersana Therapeutics, Inc. | mrsn-20191231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
(1) |
Registration Statement (Form S-3 No. 333-226055) of Mersana Therapeutics, Inc. and in the related Prospectus, |
|
(2) |
Registration Statement (Form S-8 No. 333-230159) pertaining to the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan and the Mersana Therapeutics, Inc. 2017 Employee Stock Purchase Plan, |
|
(3) |
Registration Statement (Form S-8 No. 333-222845) pertaining to the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan, and |
|
(4) |
Registration Statement (Form S-8 No. 333-219388) pertaining to the Mersana Therapeutics, Inc. 2007 Stock Incentive Plan, as amended, the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan and the Mersana Therapeutics, Inc. 2017 Employee Stock Purchase Plan; |
of our report dated February 28, 2020, with respect to the consolidated financial statements of Mersana Therapeutics, Inc. included in this Annual Report (Form 10-K) of Mersana Therapeutics, Inc. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 28, 2020